These findings extend our understanding of the mechanisms responsible for acquired resistance in cancer cells treated with KRASG12C inhibitors and indicate that Smo inhibitors are a therapeutic strategy that can overcome acquired resistance against KRASG12C inhibitors in cancers. This evidence concerns the gene SMO and cancer.